S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 168 HKD -4.27% Market Closed
Market Cap: 36.3B HKD
Have any thoughts about
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd?
Write Note

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
PP&E Gross
ÂĄ700.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
PP&E Gross
ÂĄ9.3B
CAGR 3-Years
54%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
PP&E Gross
ÂĄ2.9B
CAGR 3-Years
46%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
PP&E Gross
ÂĄ1.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
PP&E Gross
ÂĄ5.1B
CAGR 3-Years
20%
CAGR 5-Years
25%
CAGR 10-Years
24%
Imeik Technology Development Co Ltd
SZSE:300896
PP&E Gross
ÂĄ300.4m
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View

Market Cap
37.4B HKD
Industry
Biotechnology

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Chengdu, Sichuan and currently employs 1,155 full-time employees. The company went IPO on 2023-07-11. Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The firm is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The firm's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Intrinsic Value
144.55 HKD
Overvaluation 14%
Intrinsic Value
Price
S

See Also

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's PP&E Gross?
PP&E Gross
700.9m CNY

Based on the financial report for Dec 31, 2023, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's PP&E Gross amounts to 700.9m CNY.

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 1Y
7%

Over the last year, the PP&E Gross growth was 7%.

Back to Top